ViroGates AS (OCSE:VIRO) Beneish M-Score: -3.03 (As of Jun. 26, 2026)


OCSE:VIRO ViroGates AS OCSE:VIRO
44 GF Score
Price kr10.20
GF Value kr6.80
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is ViroGates AS Beneish M-Score?

ViroGates AS OCSE:VIRO 44 Beneish M-Score is -3.03 as of Jun. 26, 2026. GuruFocus rates OCSE:VIRO with a GF Score™ of 44/100 and a GF Value™ of kr6.80 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 766 Medical Devices & Instruments companies, ViroGates AS ranks better than 78.59% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.03 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for ViroGates AS's Beneish M-Score or its related term are showing as below:

OCSE:VIRO' s Beneish M-Score Range Over the Past 10 Years
Min: -4.43   Med: -2.53   Max: 0.28
Current: -3.03

During the past 10 years, the highest Beneish M-Score of ViroGates AS was 0.28. The lowest was -4.43. And the median was -2.53.


ViroGates AS Beneish M-Score Historical Data

* Premium members only.

The historical data trend for ViroGates AS's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViroGates AS Beneish M-Score Chart

ViroGates AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.05 -0.49 -3.25 -3.15 -3.56

ViroGates AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.86 -4.07 -4.43 -3.56 -3.03

OCSE:VIRO vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, ViroGates AS's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViroGates AS Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ViroGates AS's Beneish M-Score falls into.


OCSE:VIRO
44GF Score
ViroGates AS OCSE:VIRO
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ViroGates AS Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ViroGates AS for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8412+0.528 * 0.7773+0.404 * 0.615+0.892 * 1.315+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.4858+4.679 * -0.124986-0.327 * 0.7456
=-3.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was kr1.53 Mil.
Revenue was 1.303 + 2.363 + 1.673 + 3.666 = kr9.01 Mil.
Gross Profit was 0.976 + 1.948 + 1.059 + 3.082 = kr7.07 Mil.
Total Current Assets was kr26.59 Mil.
Total Assets was kr26.77 Mil.
Property, Plant and Equipment(Net PPE) was kr0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was kr0.00 Mil.
Selling, General, & Admin. Expense(SGA) was kr7.36 Mil.
Total Current Liabilities was kr6.96 Mil.
Long-Term Debt & Capital Lease Obligation was kr3.02 Mil.
Net Income was -2.611 + -2.436 + -1.93 + -3.247 = kr-10.22 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = kr0.00 Mil.
Cash Flow from Operations was -3.735 + -1.558 + -2.492 + 0.907 = kr-6.88 Mil.
Total Receivables was kr1.39 Mil.
Revenue was 1.202 + 1.568 + 3 + 1.078 = kr6.85 Mil.
Gross Profit was 0.532 + 0.78 + 2.409 + 0.455 = kr4.18 Mil.
Total Current Assets was kr15.84 Mil.
Total Assets was kr16.02 Mil.
Property, Plant and Equipment(Net PPE) was kr0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was kr0.00 Mil.
Selling, General, & Admin. Expense(SGA) was kr11.52 Mil.
Total Current Liabilities was kr3.74 Mil.
Long-Term Debt & Capital Lease Obligation was kr4.27 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.532 / 9.005) / (1.385 / 6.848)
=0.170128 / 0.202249
=0.8412

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(4.176 / 6.848) / (7.065 / 9.005)
=0.609813 / 0.784564
=0.7773

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (26.585 + 0) / 26.771) / (1 - (15.839 + 0) / 16.02)
=0.006948 / 0.011298
=0.615

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=9.005 / 6.848
=1.315

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 0)) / (0 / (0 + 0))
= /
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(7.358 / 9.005) / (11.517 / 6.848)
=0.817102 / 1.681805
=0.4858

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3.017 + 6.962) / 26.771) / ((4.273 + 3.736) / 16.02)
=0.372754 / 0.499938
=0.7456

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-10.224 - 0 - -6.878) / 26.771
=-0.124986

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

ViroGates AS has a M-score of -3.03 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.03 mean?
ViroGates AS (OCSE:VIRO) has a Beneish M-Score of -3.03 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ViroGates AS and its competitors. According to the industry distribution chart, ViroGates AS ranks #164 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 21.4%.
Is ViroGates AS's Beneish M-Score too high?
ViroGates AS's current Beneish M-Score is -3.03. Based on the distribution chart, ViroGates AS ranks #164 out of 766 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ViroGates AS has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #164 out of 766 companies for Beneish M-Score. This places ViroGates AS in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ViroGates AS and its competitors. ViroGates AS's current Beneish M-Score is -3.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.80, compared to a current price of kr10.20 — trading 50% above its estimated fair value. The current Beneish M-Score is -3.03. ViroGates AS's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current Beneish M-Score is -3.03 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?

Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued. The current stock price of kr10.20 is trading 50% above its estimated GF Value™ of kr6.80. GuruFocus considers ViroGates AS to be Significantly Overvalued.

Key valuation signals for OCSE:VIRO:

  • Beneish M-Score: -3.03
  • GF Value™: kr6.80 vs. price of kr10.20 (50% above fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ViroGates AS Business Description

Address Banevaenget 13, Birkerod, DNK, 3460
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
44GF Score

Get the complete analysis for OCSE:VIRO

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.20
Price
kr6.80
GF Value